Three cases of endometrial cancer associated with "bioidentical" hormone replacement therapy

Medical Journal of Australia

Volumn 187, Issue 4, 2007, Pages 244-245

  Eden, John A ^a,b   Hacker, Neville F ^a,b   Fortune, Michael ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL HOSPITAL FOR WOMEN   (Australia)

^c PRINCE OF WALES PRIVATE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRIOL; ESTRONE; ESTRONE SULFATE; MEDROXYPROGESTERONE ACETATE; PRASTERONE; PROGESTERONE; TESTOSTERONE; BIOLOGICAL PRODUCT;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER STAGING; CASE REPORT; CURETTAGE; ENDOMETRITIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EVENING DOSAGE; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; MENOPAUSAL SYNDROME; MORNING DOSAGE; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG FORMULATION; ENDOMETRIUM TUMOR; ESTROGEN THERAPY; MIDDLE AGED; PATHOLOGY;

AGED; BIOLOGICAL PRODUCTS; DRUG COMPOUNDING; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED;

EID: 34848913526     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb01210.x     Document Type: Article

References (7)

1. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2004; 4: 58-74.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
3. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 2003; 17: 139-147.
4. Center for Drug Evaluation and Research. Guidance for industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation [draft guidance ]. Rockville, MD: CDER, 2003. http://www.fda.gov/cder/guidance/5412dft.pdf (accessed Jul 2007).
5. North American Menopause Society. Understanding the controversy: hormone testing and bioidentical hormones. Proceedings of the Post-graduate Course prior to the 17th Annual Meeting of the North American Menopause Society. Nashville, Tennessee; 2006; 11 Oct. http:/www.menopause.org/ edumaterials/PG06monogrpah.pdf (accessed Jul 2007).
6. Australasian Menopause Society. Bioidentical hormones (troches) advice to consumers [media release ]. 29 Nov 2003. http://www.menopause.org.au/ public/media_detail.asp?ID=38 (accessed Jul 2007).
7. Australasian Menopause Society. Bioidentical hormones (troches) advice for doctors [media release]. 29 Nov 2003. http://www.menopause.org.au/ public/media_detail.asp?ID=39 (accessed Jul 2007).